Ligand Pharmaceuticals | LGND - Capital Ordinário





Capital Ordinário Alterar Data
Agenus USD 38.52M 3.2M 2026-03
Amgen USD 541M 0 2026-09
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 141.14M 564K 2026-06
Baxter International USD 517M 549K 2026-06
Bristol-Myers Squibb USD 2.04B 7M 2026-06
Eli Lilly USD 943.5M 3.33M 2026-03
Enanta Pharmaceuticals USD 212K 1000 2023-12
Enviri Corporation USD 81.45M 797K 2025-12
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 2.02B 2.05B 2026-09
Glaxosmithkline GBP 2.02B 2.03B 2026-09
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 218.28M 1.76M 2026-06
Intrexon USD 0 0 2024-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
MacroGenics USD 63.65M 86K 2026-06
Merck USD 2.47B 1.05M 2026-06
Pacira USD 39.82M 512K 2026-06
Pfizer USD 5.7B 0 2026-06
Rigel Pharmaceuticals USD 17K 158K 2024-06
Veracyte USD 80.39M 598K 2026-09